Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors
NCT06915753Phase 1Recruiting
- Sponsor
- Tyra Biosciences
- Start
- Apr 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of tyra-430 in hepatocellular carcinoma (HCC) and solid tumor (3 arms), sponsored by Tyra Biosciences. Primary endpoints: Maximum Tolerated Dose at 1 year, Adverse Events and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
tyra-430
03
Conditions
hepatocellular carcinoma (HCC)solid tumor
Beyond the preview
Go deeper on NCT06915753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06915753.